Inscription Capital LLC Sells 4,140 Shares of Johnson & Johnson $JNJ

Inscription Capital LLC reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 13.9% in the third quarter, Holdings Channel reports. The institutional investor owned 25,696 shares of the company’s stock after selling 4,140 shares during the period. Johnson & Johnson comprises about 0.7% of Inscription Capital LLC’s portfolio, making the stock its 22nd biggest holding. Inscription Capital LLC’s holdings in Johnson & Johnson were worth $6,803,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in JNJ. Wellington Management Group LLP increased its stake in shares of Johnson & Johnson by 12.5% in the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after purchasing an additional 2,513,321 shares in the last quarter. Deutsche Bank AG lifted its position in Johnson & Johnson by 8.5% during the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock valued at $3,977,506,000 after purchasing an additional 1,225,676 shares in the last quarter. Amundi lifted its position in Johnson & Johnson by 17.5% during the first quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after purchasing an additional 2,001,139 shares in the last quarter. Janus Henderson Group PLC lifted its position in Johnson & Johnson by 1.9% during the first quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company’s stock valued at $1,924,323,000 after purchasing an additional 148,497 shares in the last quarter. Finally, Jupiter Topco LLC bought a new stake in Johnson & Johnson during the second quarter valued at about $1,967,399,000. 69.55% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP Jennifer Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the sale, the executive vice president owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 0.16% of the company’s stock.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: State Street’s Health Care SPDR added J&J shares as part of a $175.3 million purchase across its portfolio, providing a modest institutional-demand signal. Article: State Street Health Care SPDR Adds Eli Lilly and J&J
• Positive Sentiment: One analyst roundup described Wall Street as moderately bullish on J&J’s prospects, following the stock’s strong performance over the past year. Article: Are Wall Street Analysts Predicting Johnson & Johnson Stock Will Climb or Sink?
• Neutral Sentiment: Several articles highlighted J&J as a long-term dividend stock, including lists of companies with long records of annual payout increases. This supports its income-investment appeal, but the pieces offer no new company-specific dividend announcement. Article: 4 Dividend Kings That Could Pay You for the Rest of Your Retirement
• Neutral Sentiment: A value-investing comparison examined J&J alongside Bayer, while another article addressed concerns that J&J shares may look expensive; the supplied headlines do not specify a valuation conclusion. Article: BAYRY vs. JNJ: Which Stock Is the Better Value Option?
• Negative Sentiment: Smith+Nephew said merger discussions with J&J’s orthopaedics unit had failed. This removes a potential transaction, though the article headline provides no details on the talks’ terms or financial implications for J&J. Article: Smith+Nephew Cuts Outlook, Confirms Failed Merger Talks with J&J’s Orthopaedics Unit

Johnson & Johnson Stock Down 1.4%

JNJ opened at $272.49 on Friday. The stock has a market cap of $655.97 billion, a price-to-earnings ratio of 41.29, a price-to-earnings-growth ratio of 2.73 and a beta of 0.22. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. The firm’s fifty day moving average is $265.71 and its 200 day moving average is $248.01. Johnson & Johnson has a fifty-two week low of $185.12 and a fifty-two week high of $282.02.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. The business had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. Johnson & Johnson’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, sell-side analysts forecast that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 81.21%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on JNJ shares. Weiss Ratings cut Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a research report on Friday, October 23rd. Royal Bank Of Canada lowered their price objective on Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 14th. Scotiabank reiterated an “outperform” rating and set a $305.00 price objective on shares of Johnson & Johnson in a research note on Thursday, July 16th. Johnson Rice lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, October 21st. Finally, The Goldman Sachs Group restated a “buy” rating and set a $282.00 target price on shares of Johnson & Johnson in a research note on Thursday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $275.92.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.